Seagen positions Tukysa combo as option for breast cancer patients with brain metastases

The com­bi­na­tion of Seagen’s Tukysa and Roche’s Kad­cy­la cut the risk of dis­ease pro­gres­sion or death by 36% in HER2-pos­i­tive breast can­cer pa­tients with brain metas­tases com­pared to Kad­cy­la alone.

The Phase III tri­al, spon­sored by Seagen, is one of the few big stud­ies prospec­tive­ly de­signed to eval­u­ate the ef­fects of new treat­ments in breast can­cer pa­tients with brain metas­tases, said Sara Hurvitz, head of hema­tol­ogy and on­col­o­gy at the Uni­ver­si­ty of Wash­ing­ton and SVP of clin­i­cal re­search at the Fred Hutchin­son Can­cer Cen­ter, in a press state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.